Document:

Exhibit 10.12

    
      

    

    
      	
              

            	
              *Nanotechhnology-Enabled
                Targeted Viricides"

            
	
              A
                Publicly Traded Company, "NNVC"

            
	
              www.nanoviricides.com

            

    

    

    

    Dec
      23,
      2005

    To

    Nguyen
      Tran
      Hien,
      MD, MPH, PhD

    Director

    National
      Institute of Hygiene and Epidemiology (NIHE)

    1
      Yersin
      Street

    Hanoi,
      Viet Nam

    

    Dear
      Dr.
      Hien:

    

    Enclosed
      please find a Memorandum of understanding between NanoViricides, Incorporated,
      USA, and NIHE, Viet Nam, as per our discussions for the purposes of cooperation
      between NanoViricides, Inc., and NIHE for novel nanotechnology-based
prevention
      strategies, therapies and diagnostics strategies for Influenza A subtype
      H5N1,

    

    We
      look
      forward to a fruitful cooperation in many areas.

    

    
      	 	
              Sincerely,

            	 
	 	
              /s/Anil
                R. Diwan

            	 
	 	
              Anil
                R. Diwan, Ph.D.

            	 
	 	
              President
                & Chairman

            	 
	 	
              NanoViricides,
                Inc.

            	 
	 	
              Mobile:
                203-606-9180

            	 
	 	
              email:
                adiwan@nanoviricides.com

            	 
	 	
              or
                adiwan@snet.net

            	 

    

     

    cc:

    Dang
      Duc
      Anh, PhD

    Vice
      Director, NIHE.

    

    

    135
      Wood
      Street, Ste. 205, West Haven, CT 06516, USA.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Memorandum
      of Understanding

    Between

    NIHE,
      Viet Nam and NanoViricides, Inc., USA

    

    NANOVIRICIDES,
      INC. 135 Wood Street, Suite 205, West Haven, CT 06516, and National
      Institute of Hygiene and Epidemiology (NIHE), 1 Yersin Street, Hanoi, Viet
      Nam,
agree
      to
      enter into a scientific research cooperation on the development of
      prevention, diagnostics,
      and therapeutic strategies for Influenza A subtype H5N1, including:

    

      
        	 	
                *

              	
                Research
                  on Novel Nanotechnology-based Vaccines
                  (NanoVaccines),

              

      

      

      
        	 	
                *

              	
                Research
                  on Novel Nanotehnology-based Therapies (NanoViricides),
                  and

              

      

      

      
        	 	
                *

              	
                Research
                  on Novel Nanotechnology-based
                  Diagnostics,

              

      

    

    

    It
      Is
      understood that these development projects will begin as small
      projects. As success
      Is achieved, the projects can be continued for further development.

    

    These
      various strategies are based on the nanotechnology intellectual property and
      products
      of NanoViricides, Inc.

    

    NanoViricides,
      Inc. shall retain all intellectual property rights to
      resulting
      products and
      technologies and shall make full efforts for world-wide protection of such
      intellectual property
      rights.

    

    Certain
      rights for the new nanotechnology products and technologies develop shall
      be
      provided to NIHE for use in Viet Nam.

    

    The
      work
      plan, costs budget, compensation and financial responsibilities of each
party
      to
      the projects shall be determined in the final Agreement.

    

    It
      Is
      understood that both parties will be sharing confidential information and
intellectual
      property of the other party, and will ensure that such information is protected
      to
      its
      fullest and not publicly disclosed except by written consent from the other
      party when
      so
      decided.

    

    Signed:
      December 23, 2005 by both parties at NIHE, Hanoi, Viet Nam

    

    
      	
              /s/
                Nguyen Tran Hien

            	 	
              /s/
                Anil R. Diwan

            	 
	
              Professor
                Nguyen Tran Hien, MD, MPH, PhD

            	 	
              Anil
                R. Diwan, Ph.D.

            	 
	
              Director

            	 	
              President
                & Chairman

            	 
	
              National
                Institute of Hygiene and Epidemiology

            	 	
              Nanoviricides,
                Inc.

            	 
	
              1
                Yersin Street

            	 	
              135
                Wood Street, Ste. 205

            	 
	
              Hanoi,
                Viet Nam

            	 	
              West
                Haven, CT 06516, USA.

            	 

    

    

    Page
      1 of
      1Exhibit 10.13

    
      

    

     

    
      

          
            **CONFIDENTIAL
              TREATMENT REQUESTED

          

          

            CERTAIN
              PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR
              CONFIDENTIAL
              TREATMENT FILED BY NANOVIRICIDES, INC. WITH THE COMMISSION. THE UN-REDACTED
              PORTIONS OF THIS EXHIBIT INCLUDING NON-PUBLIC INFORMATION HAVE BEEN
              FILED WITH
              THE COMMISSION

            

            Gencarelli
              Group

            209
              Pennsylvania Avenue, SE

            Washington,
              D.C. 20003

            (202)543-6972

            

            December
              29, 2006

            

            Eugene
              Seymour, MD

            Chief
              Executive Officer

            Nanoviricides,
              Inc.

            135
              Wood
              Street, Suite 205

            West
              Haven, Connecticut 06516

            

            Re:
              Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
              Agencies and International Health Agencies, 2006-2007

            

            Dear
              Dr.
              Seymour:

            

            I
              am
              writing to establish a record of work done in recent months to put
              in

            place
              formal collaborative arrangements between Nanoviricides, Inc. and U.S.
              Federal
              research agencies.

            

            U.S.
              Military—wwwwww xxxx xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxx

            

            In
              June
              of 2006 Nanoviricides, Inc. began discussions with Colonel xxxxx xxxxx,
              Chief,
              xxxxxxxxxx xxxxxxxxx xxxxx, about possible common interests and

            goals
              in
              the area of anti-viral treatment research. This meeting led to technical
              discussions in September wherein Colonel xxxxxx xxxxxx xxxxxx, Ph.D.,
              Director,
              xxxxxxxx xx xxxxx xxxxxxxxx xxxxx, initiated dialogue with Nanoviricides,
              Inc.
              about a Cooperative Research and Development Agreement (CRADA) designed
              to test
              the effectiveness of the Nanoviricides, Inc. anti-viral approach against
              three
              diseases of interest at xxxxx, namely Dengue Fever, West Nile Virus
              and Japanese
              Equine Encephalitis (JEE). 

            

            As
              of
              December 22, 2006, Nanoviricides, Inc. officials have submitted required
              information for formalization of the CRADA and await sign-off by WRAIR
              officials
              so that work can begin within 45-60 days. This work will initially
              test a
              combination of the Nanoviricides, Inc. polymer and targeting antibody
              fragments
              derived from the specified diseases against the three diseases themselves
              in an
              in vitro setting. When these in vitro tests show adequate effectiveness,
              it is
              xxxxx’s intention to continue testing with this combination in primates where
              Dengue fever will be the primary focus. Nanoviricides, Inc. can reasonably
              expects both of these experimental tracks to move forward during the
              2007
              calendar year.

            
              
                
                

              

              
                
                

                
                  

                

              

              
                
                

                **CONFIDENTIAL
                  TREATMENT REQUESTED

              

            

            Page
              2-Nanoviricides, Inc. Collaboration with U.S. Military and Civilian
              Research
              Agencies, 2006-2007

            

            United
              States National xxxxxxxxx xxx xxxxxxxxx xxx xxxxxxxxxx xxxxxxx
              xxxxxxxxxx

            

            Nanoviricides,
              Inc. began discussions in September of this year with Dr. xxxxxx xxxxxxxxxxx
              Chief, Influenza, SARS, and Other Viral Respiratory Diseases Section
              Division
              of Microbiology
              and Infectious Diseases xxxxxxxxxxxxx, and program manager xxxxxxx
              xxxxxxxxxx
              about participating in xxxxx’s Small business testing and 

            evaluation
              program which provides no-cost testing of novel immunotherapeutic treatment
              and
              vaccines against diseases considered priorities for the Institute.
              Nanoviricides, Inc. and xxxxx are now in the process of finalizing
              paperwork for
              bioassay (in vitro) testing to be done against HIV (AIDS), Influenzas,
              H5N1,
              SARS, and Herpes over the next few months. Assuming adequate effectiveness
              is
              shown in the in vitro testing, the goal will be to move on to animal
              studies on
              the same diseases. Actual experimentation will be done by xxxxx contractor
              xxxx
              xxxxx with all costs (other than production of Nanoviricides, Inc.
              materials)
              borne by xxxxx. xxxxx has indicated that if there are no unforeseen
              delays, both
              bioassay and animal studies could begin before the end of calendar
              year
              2007.

            

            Also
              in
              2006, Nanoviricides, Inc. has spent time exploring possible collaboration
              opportunities with foreign research institutes under the auspices of
              the xxx
              xxxxxxxx xxxxxx xxxxxxxxxxxx and the xxxxx xxxxxx xxxxxxxxxxxx. The
              company has
              met on numerous occasions with Dr. xxxx xxxxxxxxx xx xxxx, well known
              for his
              efforts to bring novel pharmaceutical solutions to populations in underdeveloped
              countries where “orphan” or “neglected” disease take an inordinate toll on
              indigenous peoples. One of his most important contributions has been
              arrangement
              of collaborations with the pharmaceutical industry which have significantly
              reduced river blindness sickness in Africa. With Dr. xxxxxxxxx’s encouragement,
              Nanoviricides, Inc. has met with Dr. xxxxxx xxxxxx, Executive Director,
              Tropical
              Disease Research Institute of the xxx, in Washington, DC and later
              in Geneva,
              Switzerland to identify target diseases and research institutes in
              South and
              Central America which that may be potential collaborators. This work
              is expected
              to produce commercial and humanitarian opportunities relating to diseases
              common
              to this region of the world.

            

            I
              hope
              this summary adequately explains the state of play between Nanoviricides,
              Inc.
              and two key government collaborators. Gencarelli Group stands ready
              to answer
              detailed questions on these projects.

            

            
              	 	
                      Dave
                        Gencarelli, Gencarelli Group 

                    
	 	
                      202-256-6191

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]